Table 1.
Participant characteristics
| Group | Diagnose | N | Agea | CA125 U/mlb |
|---|---|---|---|---|
| Controls | Healthy | 40 | 52.3 (3.8) | n.a. |
| OC-BDc | 16 | 48.7 (9.0) | n.a. | |
| Benign | 7 | 46.4 (10.2) | n.a. | |
| Borderline | 1 | 35 | n.a. | |
| - Stage I | 1 | 35 | n.a. | |
| Malign | 8 | 52.4 (6.0) | n.a. | |
| - Stage I | 2 | 49.8 (3.0) | n.a. | |
| - Stage II | 2 | 48.7 (11.5) | n.a. | |
| - Stage III | 3e | 54.4 (4.4) | n.a. | |
| - Stage IV | 1 | 57.8 | n.a. | |
| OC-ADd | 100 | 58.1 (14.4) | 95.0 (124.5) | |
| Benign | 38 | 54.3 (16.8) | 26.0 (17.8) | |
| Borderline | 10 | 51.0 (14.2) | 73.0 (63.0) | |
| - Stage I | 10 | 51.0 (14.2) | 73.0 (63.0) | |
| Malign | 52 | 62.3 (11.8) | 421.5 (494.4) | |
| - Stage I | 15 | 62.5 (13.2) | 93.0 (83.0) | |
| - Stage II | 5 | 67.0 (10.6) | 71.0 (57.8) | |
| - Stage III | 20 | 60.2 (13.7) | 889.0 (738.3) | |
| - Stage IV | 12 | 63.5 (6.7) | 774.0 (285.4) |
a
Reported as mean (std. dev) at sample collection.
b
Clinically measured MUCIN-16 (CA125) reported as median (median abs. dev.) at time of diagnosis.
c
OC-BD, samples with ovarian cancer suspicion collected before diagnosis.
d
OC-AD, samples with ovarian cancer suspicion collected at time of diagnosis.
e
Two samples from the same women collected at different time-points. n.a: not available.